HIV Patient Thrives at 74 with New FDA-Approved Treatment

By VirentaNews Staff — May 10, 2026

In 1996, Barbara Roberts was told she had HIV—and given just years to live. At the time, an HIV diagnosis was often a death sentence, with life expectancy measured in months for many. But three decades later, Roberts, now 74, is not only alive but thriving, thanks to groundbreaking advancements in antiretroviral therapy. She is part of a growing cohort of long-term HIV survivors who are redefining what it means to age with the virus. Today, nearly 50% of people living with HIV in the United States are aged 50 or older, according to the Centers for Disease Control and Prevention (CDC), a seismic shift from the epidemic’s early years when few survived into middle age, let alone beyond. Roberts’ journey reflects both the resilience of patients and the transformative power of sustained medical innovation in HIV care.

A New Era in HIV Management

Roberts’ survival is emblematic of a broader public health success story: the evolution of HIV from a fatal illness to a manageable chronic condition. When she was diagnosed at 44, combination antiretroviral therapy (ART) was just emerging, and treatment regimens were harsh, with debilitating side effects and multiple daily pills. Many patients struggled with adherence, and drug resistance was common. Now, at 74, Roberts benefits from a once-monthly injectable medication recently approved by the U.S. Food and Drug Administration (FDA)—a regimen that replaces the daily pill burden she managed for over 25 years. This new treatment, known as lenacapavir (brand name Sunlenca), represents a paradigm shift for long-term HIV patients, particularly older adults who face challenges with polypharmacy and age-related cognitive decline. Its approval in 2022 and expanded use in 2023 mark a milestone in the pursuit of long-acting, patient-friendly therapies.

From Daily Pills to Monthly Injections

The new treatment regimen has transformed Roberts’ daily life. For decades, she took a cocktail of pills every morning and night, carefully timing doses to avoid food interactions and manage side effects like nausea and fatigue. The psychological toll of constant medication reminders was significant. “Every pill was a reminder of my diagnosis,” she said in a recent interview. The monthly injection, administered by a healthcare provider, has lifted that burden. Lenacapavir, developed by Gilead Sciences, is a capsid inhibitor that disrupts multiple stages of the HIV lifecycle, making it effective even in treatment-experienced patients with resistant strains. Clinical trials showed that over 90% of participants maintained viral suppression after switching to the long-acting regimen. For older adults like Roberts, the reduction in pill burden improves quality of life and reduces the risk of drug interactions with medications for hypertension, diabetes, or heart disease—conditions that become more common with age.

Why Aging with HIV Presents Unique Challenges

While medical advances have extended life expectancy, aging with HIV brings complex health challenges. People with HIV are at higher risk for accelerated aging, including earlier onset of cardiovascular disease, osteoporosis, neurocognitive decline, and certain cancers—conditions that may be driven by chronic inflammation and immune activation, even when the virus is suppressed. A 2023 study published in Nature Medicine found that individuals with HIV exhibit biological aging markers up to five years ahead of their chronological age. This “premature aging” phenomenon underscores the need for specialized care models that integrate HIV treatment with geriatric medicine. As the population of long-term survivors grows—projected to exceed 70% of all people with HIV in the U.S. by 2030—health systems must adapt to address both the virus and the comorbidities of aging.

Expanding Access to Long-Acting Therapies

The promise of long-acting HIV treatments like lenacapavir is tempered by access barriers. The medication remains expensive, with a list price exceeding $40,000 annually, and insurance coverage varies widely. Rural patients may lack providers trained to administer the injection, and stigma around HIV persists, particularly among older adults who associate the virus with the epidemic’s darkest years. Yet, the FDA’s approval signals growing recognition of the need for patient-centered innovation. Other long-acting options, including injectable cabotegravir and rilpivirine, are already in use, and research into implantable devices and annual injections is underway. For Roberts, the treatment is more than medical—it’s symbolic. “It tells me that science hasn’t forgotten us,” she said. “We’re still worth investing in.”

Expert Perspectives

Medical experts agree that long-acting therapies are reshaping HIV care. “For patients who’ve lived with this virus for decades, reducing treatment burden is critical to maintaining adherence and quality of life,” said Dr. Monica Gandhi, an infectious disease specialist at the University of California, San Francisco. However, some caution against overreliance on new drugs without addressing systemic inequities. “Innovation means nothing if it only reaches the privileged,” warned Dr. Oni Blackstock, founder of Health JusticeFDN. “We must ensure these advances reach Black and Latino communities, women, and older adults who are often left behind.”

Looking ahead, the focus is shifting toward personalized, holistic care for aging HIV patients. Researchers are exploring biomarkers of accelerated aging and testing interventions to reduce inflammation. With Barbara Roberts and others proving that long-term survival is possible, the next frontier is ensuring that longevity comes with dignity, health, and equity.

Source: Healthline